Latest Breaking News On - Clinical cure - Page 4 : comparemela.com

Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)

Acurx Pharmaceuticals, Inc. stock is getting massive interest. Of course, the question is- why? Speculation is that its related to ACXP nearing a data release for its Phase 2b clinical trial.

United statesEquities incHawk point media group llcAcurx pharmaceuticalsTrial oversight committeeHawk point media groupAcurx pharmaceuticals incFront line designation to treatClinical cureBig pharmaOversight committeeAdvisory boardPoint media groupPrivate securities litigation reform actHawk point

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for C. difficile Infection; effects on toxin production, biofilm and the gut microbiomeA.

United statesKevin gareyMichael silvermanJinhee joRobertj delucciaEugenie basseresSociety or healthcare epidemiology of americaDrug administrationUniversity of houstonAcurx pharmaceuticals incMedicine associationInfectious diseases society of americaData monitoring committeeCompany phInternational conference on molecular biologyPediatric infectious diseases society

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C difficile Infection

Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as.

United statesDavidp luciRobertj delucciaData monitoring committeeInfectious diseases society of americaSociety for healthcare epidemiology of americaTrial oversight committeeDrug administrationPrnewswire acurx pharmaceuticals incCompany annual report on formAcurx pharmaceuticalsExchange commissionAcurx pharmaceuticals incClinical cureFast track designatedIndependent data monitoring committee

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Vu truongAridis pharmaceuticals incEuropean medicines agencyAridis pharmaceuticalsExchange commissionRedchip companies incCommunity acquiredpneumoniaMarketing authorization applicationClinical cureSerious adverse eventsVentilator associated pneumoniaHospital acquiredpneumoniaChip companies

Why Are Aridis Pharmaceuticals Shares Moving Higher Today?

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301. AR-301 is being developed as an adjunctive therapy with standard-of-care (SOC) antibiotics for pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitalized patients. Key agreements by the EMA were similar to those a

European medicines agencyAridis pharmaceuticals incWhy are aridis pharmaceuticals shares moving higherClinical cureBenzinga proAdjunctive therapyEuropean medicines agencyOlder adultsAridis pharmaceuticalsStaphylococcus aureus